ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print April 30, 2008
Eur Respir J 2008, doi:10.1183/09031936.00022308
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
32/3/718    most recent
09031936.00022308v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by French, C.E.
Right arrow Articles by Abubakar, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by French, C.E.
Right arrow Articles by Abubakar, I.


ORIGINAL ARTICLE

The association between HIV and anti-tuberculosis drug resistance in England and Wales

C.E. French 1*, J.R. Glynn 2, M.E. Kruijshaar 1, I.C. Ditah 3, V. Delpech 4, I. Abubakar 1

1 Tuberculosis Section, Respiratory Diseases Dept, Health Protection Agency Centre for Infections, London, United Kingdom
2 Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
3 University of East Anglia, Norwich, United Kingdom
4 HIV and AIDS Reporting Section, HIV and STI Dept, Health Protection Agency Centre for Infections, London, United Kingdom

* To whom correspondence should be addressed. E-mail: clare.french{at}hpa.org.uk.


   Abstract

In the UK, HIV is considered to be a risk factor for anti-tuberculosis drug resistance. Evidence on the association is, however, inconclusive and there is little population level data. This study investigated the association in England and Wales during 1999-2005.

National tuberculosis surveillance data for adults were matched to HIV/AIDS reports. Unmatched cases were assumed to be HIV-negative. Separate analyses were conducted on new tuberculosis cases and those with a previous diagnosis. Logistic regression was used for univariable and multivariable analyses.

There were 1657 previously diagnosed cases (80 HIV-positive) and 18, 130 new cases (1156 HIV-positive). Isoniazid resistance was found in 8.1% of previously diagnosed cases and 6.6% of new cases, and multidrug resistance (MDR) in 2.8% and 0.7% respectively. There was no evidence of an association between HIV and anti-tuberculosis drug resistance among previously diagnosed cases. Among new cases, there was no overall association between HIV and isoniazid resistance or MDR after adjusting for confounding factors. White HIV-positive patients were more likely to have MDR, but numbers were small.

In contrast to some previous studies, this large up-to-date study provides little evidence that HIV co-infected tuberculosis patients in England and Wales are at increased risk of first-line anti-tuberculosis drug resistance.

Keywords:  Anti-tuberculosis drug resistance, England and Wales, HIV, Tuberculosis




This article has been cited by other articles:


Home page
Int J STD AIDSHome page
P Tabarsi, E Chitsaz, A Moradi, P Baghaei, P Farnia, M Marjani, P Irannejad, D Mansouri, and M Masjedi
First-line antituberculosis drug resistance prevalence and its pattern among HIV-infected patients in the national referral tuberculosis centre, Iran
Int J STD AIDS, August 1, 2009; 20(8): 566 - 570.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the European Respiratory Society.